Goodwin Procter LLP advised Jounce Therapeutics on the deal. Jounce Therapeutics (Nasdaq: JNCE) announced its agreement with Gilead Sciences (Nasdaq: GILD) to exclusively license its JTX-1811…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
